|
Extramural Support
|
RMS2013 [E]
|
$366,054,072
|
$771,696
|
N/A
|
National Cancer Institute
|
|
Defining mechanisms of cancer chemoresistance and metastasis
|
1K99CA172697-01
|
$158,535
|
$158,535
|
Acharyya, Swarnali
|
SLOAN-KETTERING INST CAN RES
|
|
Children's Oncology Group Chair's Grant
|
5U10CA098543-11
|
$24,894,951
|
$24,894,951
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Mesothelin as a biomarker for clinical management of esophageal adenocarcinoma
|
5R21CA164585-02
|
$186,970
|
$93,485
|
Adusumilli, Prasad
|
SLOAN-KETTERING INST CAN RES
|
|
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
|
3R01CA140368-04S1
|
$48,000
|
$48,000
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Prostate Cancer Prevention and Treatment by Silibinin
|
5R01CA102514-10
|
$303,143
|
$151,572
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
|
5R01CA140368-04
|
$285,463
|
$285,463
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
5R44CA124032-05
|
$1,806,651
|
$1,806,651
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
2U54CA137788-06
|
$983,895
|
$118,067
|
Ahles, Tim
|
SLOAN-KETTERING INST CAN RES
|
|
CCNY-MSKCC Partnership for Cancer Research, Training & Community Outreach (1 of 2
|
3U54CA137788-06S1
|
$168,224
|
$20,187
|
Ahles, Tim
|
SLOAN-KETTERING INST CAN RES
|
|
Participation in the Eastern Cooperative Oncology Group
|
5U10CA107868-10
|
$13,680
|
$13,680
|
AISNER, JOSEPH
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
Participation in the Eastern Cooperative Oncology Group
|
7U10CA107868-11
|
$160,010
|
$160,010
|
AISNER, JOSEPH
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction
|
1R01CA172741-01A1
|
$279,793
|
$279,793
|
Ajani, Jaffer
|
UT MD ANDERSON CANCER CTR
|
|
Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
|
5R01CA138671-04
|
$291,367
|
$291,367
|
Ajani, Jaffer
|
UT MD ANDERSON CANCER CTR
|
|
Molecular Interaction Maps and Analysis of Bioregulatory Networks
|
ZIA BC 010562
|
$84,142
|
$4,207
|
Aladjem, Mirit
|
CCR (NCI)
|
|
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer
|
1R01CA172921-01A1
|
$357,673
|
$178,837
|
Albelda, Steven
|
UNIVERSITY OF PENNSYLVANIA
|
|
Immuno/Immuno-Gene Therapies for Thoracic Malignancies
|
5P01CA066726-16
|
$1,111,842
|
$211,250
|
Albelda, Steven
|
UNIVERSITY OF PENNSYLVANIA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-35S1
|
$75,000
|
$4,500
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Combined Acoustic Imaging and Viscoelastic Parameters Estimation in Breast Cancer
|
3R01CA148994-03S1
|
$72,598
|
$36,299
|
Alizad, Azra
|
MAYO CLINIC ROCHESTER
|
|
Combined Acoustic Imaging and Viscoelastic Parameters Estimation in Breast Cancer
|
5R01CA148994-03
|
$395,520
|
$197,760
|
Alizad, Azra
|
MAYO CLINIC ROCHESTER
|
|
Cdk-2 Independent role of cyclin E in Cell survival
|
5R01CA127264-05
|
$296,611
|
$296,611
|
Almasan, Alexandru
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-44S1
|
$116,998
|
$3,510
|
Altieri, Dario
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-44
|
$2,308,335
|
$69,250
|
Altieri, Dario
|
WISTAR INSTITUTE
|
|
Exploiting altered glucose utilization in Bcr-Abl+ Leukemia
|
5F31CA157166-04
|
$42,232
|
$42,232
|
Alvarez-Calderon, Francesca
|
UNIVERSITY OF COLORADO DENVER
|
|
Genome-Wide Predictors of Treatment-Related Toxicities
|
5R01CA139426-03
|
$927,470
|
$927,470
|
Ambrosone, Christine
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Novel Markers for Disease Outcome in Breast Cancer
|
ZIA BC 010887
|
$477,407
|
$95,481
|
Ambs, Stefan
|
CCR (NCI)
|
|
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE
|
5U01CA151452-04
|
$386,926
|
$386,926
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
PARP Inhibition to Treat Triple-Negative Breast Cancer Brain Metastases
|
5K23CA157728-03
|
$173,089
|
$173,089
|
Anders, Carey
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
SPORE in Multple Myeloma
|
2P50CA100707-11A1
|
$2,150,500
|
$1,290,300
|
Anderson, Kenneth
|
DANA-FARBER CANCER INST
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
5R01CA050947-21
|
$262,054
|
$131,027
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Children's Oncology Group Statistics and Data Center Grant
|
5U10CA098413-11
|
$5,797,460
|
$5,797,460
|
ANDERSON, JAMES
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
In vivo detection of involvement of endogenous BM progenitor cells in glioma
|
5R01CA172048-02
|
$285,749
|
$142,875
|
ARBAB, ALI
|
HENRY FORD HEALTH SYSTEM
|
|
Anthraycline-related cardiotoxicity in long-term survivors of lymphoma
|
1R21CA178344-01
|
$189,963
|
$189,963
|
ARMENIAN, SARO
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Longitudinal Cardiotoxicity in Adult Survivors Childhood Cancer
|
5R01CA157838-02
|
$564,229
|
$564,229
|
Armstrong, Gregory
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Targeting to Epigenetic Modications in ALL
|
5R01CA176745-03
|
$378,115
|
$378,115
|
ARMSTRONG, SCOTT
|
SLOAN-KETTERING INST CAN RES
|
|
SPORE in Breast Cancer
|
2P50CA098131-11
|
$2,150,500
|
$537,625
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY MED CTR
|
|
Image-guided combination therapy: noninvasive assessment of delivery and response
|
5R01CA154738-03
|
$550,456
|
$550,456
|
ARTEMOV, DMITRI
|
JOHNS HOPKINS UNIVERSITY
|
|
Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy
|
5K22CA160725-03
|
$195,961
|
$97,981
|
Astsaturov, Igor
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy
|
7K22CA160725-04
|
$195,961
|
$97,981
|
Astsaturov, Igor
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Southeast Cancer Control Consortium, Inc
|
5U10CA045808-27
|
$1,874,946
|
$712,479
|
Atkins, James
|
SOUTHEAST CANCER CONTROL CONSORTIUM
|
|
Eastern Cooperative Oncology Group Studies
|
3U10CA014548-38S1
|
$334,918
|
$334,918
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Using FAP to Selectively Target Epithelial Cancers
|
5R01CA163930-02
|
$334,999
|
$167,500
|
BACHOVCHIN, WILLIAM
|
TUFTS UNIVERSITY BOSTON
|
|
ENGINEERED INTELLIGENT MICELLE FOR TUMOR pH TARGETING
|
5R01CA101850-09
|
$247,262
|
$247,262
|
Bae, You
|
UNIVERSITY OF UTAH
|
|
Metformin as a Novel Chemotheraeutic Strategy for the Treatment of Endometrial Ca
|
5K23CA143154-04
|
$170,873
|
$170,873
|
Bae-Jump, Victoria
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
San Juan Minority-Based Community Clinical Oncology Program
|
2U10CA052667-23
|
$573,647
|
$229,459
|
BAEZ, LUIS
|
SAN JUAN HEALTH DEPARTMENT
|
|
Tyrosine kinase inhibitors for the treatment of childhood AML
|
5R01CA138744-04
|
$317,854
|
$317,854
|
Baker, Sharyn
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Dartmouth Center for Cancer Nanotechnology Excellence
|
5U54CA151662-04
|
$2,138,631
|
$171,090
|
Baker, Ian
|
DARTMOUTH COLLEGE
|
|
Ras-Induced Lung Cancer: Key Roles for IKK and NF-kappaB
|
5R01CA073756-14
|
$237,227
|
$47,445
|
BALDWIN, ALBERT
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Cancer-Associated, Interdependent Regulation of mTOR, AKT, and IKK/NF-kappaB
|
5R01CA075080-15
|
$277,527
|
$277,527
|
BALDWIN, ALBERT
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Regulation of Basal-Like and Her2+ Breast Cancer Phenotypes by IKK/NF-kappaB
|
5R01CA138937-04
|
$278,795
|
$69,699
|
BALDWIN, ALBERT
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
Total relevant funding to Chemotherapy for this search: $466,489,513
|